Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE

Abstract

Regimens based on Bruton's tyrosine kinase inhibitors (BTKi) have been increasingly used to treat mantle cell lymphoma (MCL). A real‐world multicenter study was conducted to characterize treatment patterns and outcomes in patients with newly diagnosed MCL by Chinese Hematologist and Oncologist Innovation Cooperation of the Excellent (CHOICE). The final analysis included 1261 patients. Immunochemotherapy was the most common first‐line treatment, including R‐CHOP in 34%, cytarabine‐containing regimens in 21% and BR in 3% of the patients. Eleven percent (n = 145) of the patients received BTKi‐based frontline therapy. Seventeen percent of the patients received maintenance rituximab. Autologous hematopoietic stem cell transplantation (AHCT) was conducted in 12% of the younger (<65 years) patients. In younger patients, propensity score matching analysis did not show significant difference in 2‐year progression‐free survival and 5‐year overall survival rate in patients receiving standard high‐dose immunochemotherapy followed by AHCT than induction therapy with BTKi‐based regimens without subsequent AHCT (72% vs 70%, P = .476 and 91% vs 84%, P = .255). In older patients, BTKi combined with bendamustine plus rituximab (BR) was associated with the lowest POD24 rate (17%) compared with BR and other BTKi‐containing regimens. In patients with resolved hepatitis B at the baseline, HBV reactivation rate was 2.3% vs 5.3% in those receiving anti‐HBV prophylaxis vs not; BTKi treatment was not associated with higher risk of HBV reactivation. In conclusion, non‐HD‐AraC chemotherapy combined with BTKi may be a viable therapeutic strategy for younger patients. Anti‐HBV prophylaxis should be implemented in patients with resolved hepatitis B.